Treatment strategies of intermediate-stage hepatocellular carcinomas in Japan (Barcelona clinic liver cancer stage B)

Oncology (Switzerland)

Volumn 87, Issue , 2014, Pages 78-81

  Yamakado, Koichiro ^a   Kudo, Masatoshi ^b  

^a Graduate School of Medicine   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemoembolization; Child Pugh score; Hepatocellular carcinoma; Intermediate stage; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; SORAFENIB;

ALGORITHM; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CLINICAL PRACTICE; CONFERENCE PAPER; CONSENSUS; EVIDENCE BASED PRACTICE; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER RESECTION; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TREATMENT FAILURE; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; EVIDENCE BASED MEDICINE; HEPATIC ARTERY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER NEOPLASMS; PATHOLOGY; PROGNOSIS; REGIONAL PERFUSION;

ALGORITHMS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CONSENSUS; EVIDENCE-BASED MEDICINE; HEPATECTOMY; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; JAPAN; LIVER NEOPLASMS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS;

EID: 84922480447     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000368149     Document Type: Conference Paper

References (27)

1. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
2. Kim DY, Han KH: Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012; 1: 2-14.
3. Llovet JM, Ducreux M, et al: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
4. Japan Society of Hepatology: Clinical Practice Guidelines for Hepatocellular Carcinoma (2013 Version). Kanehara, Tokyo, 2013.
5. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M: Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-364.
6. Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer 2012; 1: 41-50.
7. Belghiti J, Fuks D: Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer 2012; 1: 71-82.
8. Mise Y, Sakamoto Y, Ishizawa T, Kaneko J, Aoki T, Hasegawa K, Sugawara Y, Kokudo N: A worldwide survey of the current daily practice in liver surgery. Liver Cancer 2013; 2: 55-66.
9. Lin SM: Local ablation for hepatocellular carcinoma in Taiwan. Liver Cancer 2013; 2: 73-83.
10. Kudo M: Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012; 1: 62-70.
11. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.
12. Llovet JM, Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327.
13. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C: A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010; 51: 1274-1283.
14. Lee NH, Chau GY, Lui WY, King KL, Tsay SH, Wu CW: Surgical treatment and outcome in patients with a hepatocellular carcinoma greater than 10 cm in diameter. Br J Surg 1998; 85: 1654-1657.
15. Poon RT, Fan ST, Wong J: Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg 2002; 194: 592-602.
16. Liau KH, Ruo L, Shia J, Padela A, Gonen M, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH, DeMatteo RP: Outcome of partial hepatectomy for large (>10 cm) hepatocellular carcinoma. Cancer 2005; 104: 1948-1955.
17. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, Imamura H, Sugawara Y, Kokudo N, Makuuchi M: Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-1916.
18. Ho MC, Huang GT, Tsang YM, Lee PH, Chen DS, Sheu JC, Chen CH: Liver resection improves the survival of patients with multiple hepatocellular carcinomas. Ann Surg Oncol 2009; 16: 848-855.
19. Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L, Ye XP, Peng T, Xie GS, Li LQ: Hepatic resection associated with good survival for selected patients with intermediate and advancedstage hepatocellular carcinoma. Ann Surg 2013, Epub ahead of print.
20. Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S, Omata M: Combination therapy of intraarterial 5-fluorouracil and systemic interferonalpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-1997.
21. Yamakado K, Nakatsuka A, Takaki H, Yokoi H, Usui M, Sakurai H, Isaji S, Shiraki K, Fuke H, Uemoto S, Takeda K: Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology 2008; 247: 260-266.
22. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, Raoul JL, Sangro B: Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012; 32: 348-359.
23. Ha Y, Shim JH, Kim SO, Kim KM, Lim YS, Lee HC: Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. J Gastroenterol Hepatol 2014; 29: 787-793.
24. Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, Maeda H, Matsuo K, Nishida N, Aramaki T, Anai H, Koura S, Oikawa S, Watanabe K, Yasumoto T, Furuichi K, Yamaguchi M: Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol 2014; 32: 260-265.
25. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
26. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
27. Iwasa S, Ikeda M, Okusaka T, Ueno H, Morizane C, Nakachi K, Mitsunaga S, Kondo S, Hagihara A, Shimizu S, Satake M, Arai Y: Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Jpn J Clin Oncol 2011; 41: 770-775.